Syndax Pharmaceuticals (SNDX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

SNDX Syndax Pharmaceuticals

Watchlist

14.920
-0.160-1.06%

Close Feb 14 16:00 ET

14.920
0.0000.00%

Post 17:01 ET

1.27BMarket Cap-4.10P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Have Syndax Pharmaceuticals Insiders Been Selling Stock?
Simply Wall StFeb 15 07:13 ET
Express News | Syndax Pharmaceuticals Inc : Guggenheim Cuts Target Price to $32 From $35
ReutersFeb 13 06:49 ET
Is Syndax Pharmaceuticals (NASDAQ:SNDX) In A Good Position To Invest In Growth?
Simply Wall StFeb 7 06:14 ET
Syndax Pharmaceuticals Up Over 9%, on Pace for Largest Percent Increase Since December 2022 -- Data Talk
Dow JonesFeb 6 14:11 ET
Kura Oncology Falls Despite Trial Success; Rival Syndax Gains
Seeking AlphaFeb 6 11:28 ET
Express News | Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersFeb 4 16:05 ET

Comments

Trytosaveabit

Dec 9, 2024 06:45

Update

$Syndax Pharmaceuticals (SNDX.US)$ Reuters· 11 mins ago
Syndax Pharmaceuticals: Subgroup Analyses From Ph 2 Protocol-Defined R/R Mnpm1 Aml Efficacy Population Show Responses Across All Major Subgroups

Jaguar8

Nov 17, 2024 13:32

J.P. Morgan analyst has maintained their bullish stance on stock, giving a Buy rating on November 13. Goldman Sachs give it price target $31.

$Syndax Pharmaceuticals (SNDX.US)$

Jaguar8

Nov 16, 2024 16:41

My watchlist Monday. Why? FDA approval- first of its kind for acute adult and pediatric leukemia

$Syndax Pharmaceuticals (SNDX.US)$

Trytosaveabit

Nov 15, 2024 18:07

Repost of FDA approval! Longer PR because to me this seems like a pretty big deal? More so than most approvals! JMO

$Syndax Pharmaceuticals (SNDX.US)$ But im sure/hoping Dr @Jaguar8 will either confirm or dispute! To me seems pretty AWESOME! ((((((. Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
1 HOUR AGO, 5:29 PM EST
VIA PR NEWSWIRE
– Approva...

Jaguar8

Nov 15, 2024 16:32

NEWS RECAP

$Syndax Pharmaceuticals (SNDX.US)$
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

SNDX Syndax Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Trending Stocks